PSMA

Beyond's analysis on PSMA

• 2026-09-09 — InnoCare secures Chinese IND clearance for its first bispecific ADC, ICP‑B381, targeting PSMA and STEAP1, marking a new clinical‑stage asset in the fast‑growing Chinese oncology pipeline

Recent news mentioning PSMA

• 2026-09-09 — InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
• 2026-09-02 — Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
• 2026-08-05 — Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
• 2026-07-31 — FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

Appears alongside

• China
• InnoCare
• ADC
• STEAP1
• FDA
• Pluvicto

Browse the full archive →